Sign Up
Stories
Advancements in Cancer Treatment
Share
Advanced Cancer Therapies Show Promising...
Oncology Innovations Showcase at AACR
Advancing CD70 Targeted Cancer Treatment...
Bayer's BAY 2927088 Breakthrough Therapy...
CDR-Life's FDA Clearance for Precision I...
Overview
API
Advancements in cancer treatment: Bristol Myers Squibb's CheckMate -67T trial evaluates the noninferiority of a subcutaneous Opdivo formulation compared to intravenous Opdivo in advanced or metastatic clear cell renal cell carcinoma. Merck's KEYTRUDA demonstrates a 38% reduction in the risk of death as adjuvant therapy for patients with renal cell carcinoma at increased risk of recurrence following nephrectomy.
Ask a question
How could the approval of KEYTRUDA for adjuvant treatment of RCC and Merck's broad clinical development program influence the future of cancer treatment?
How might the potential practice-changing advancement of the subcutaneous Opdivo formulation impact the treatment landscape for patients with advanced or metastatic clear cell renal cell carcinoma?
What are the broader implications of the significant 38% reduction in the risk of death for patients with renal cell carcinoma at increased risk of recurrence following nephrectomy?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage